Dec 9 (Reuters) - Sirtex Medical Ltd SRX.AX :
* On a full year basis, worldwide dose sales growth is anticipated to be in order of 5-11% compared to growth of 16.4% achieved in fy16
* Constant currency EBITDA for full year is anticipated to be in range $65-74 million Source text for Eikon: ID:nASX7jgkL3 Further company coverage: SRX.AX